Premium
Integrating New Pharmacologic Agents into Heart Failure Care: Role of Heart Failure Practice Guidelines in Meeting This Challenge
Author(s) -
Adams Kirkwood F.,
Giblin Erika M.,
Pearce Natalie,
Patterson J. Herbert
Publication year - 2017
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.1934
Subject(s) - heart failure , ivabradine , medicine , sacubitril, valsartan , intensive care medicine , context (archaeology) , sacubitril , guideline , ejection fraction , valsartan , adverse effect , cardiology , blood pressure , heart rate , paleontology , pathology , biology
Heart failure is well recognized as a major public health concern not only due to severe and frequent adverse health outcomes but also related to the major financial burden this syndrome presents with advancing age in Western societies. Despite the dire need for more efficacious therapies and better application of existing advances, treatment gaps persist, and outcomes in heart failure remain poor, with continually high mortality and morbidity. Treatment guidelines provide one strategy for advancing quality of care in patients with heart failure. This approach, with well‐known potential strengths and weaknesses, has both adherents and detractors. Heart failure treatment guidelines have been in sharp focus recently due to updates that address the United States Food and Drug Administration ( FDA ) approval in 2015 of two new pharmacologic therapies for heart failure with reduced ejection fraction: sacubitril‐valsartan and ivabradine. Our commentary will revisit issues in guideline methodology and discuss these in the context of the updates addressing the FDA approval of new pharmacologic agents for heart failure with reduced ejection fraction.